Neoadjuvant immunotherapy for locally advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This Phase 3 study tests how well immunotherapy given before surgery (neoadjuvant treatment) works for locally advanced stomach cancer. It aims to improve outcomes by tailoring treatment to different “immunotypes” (how the immune system and tumor behave).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old (all sexes).
- You have stomach cancer confirmed by pathology, and the type includes papillary, tubular, mucinous, signet ring, or poorly differentiated.
- Your scans show it has grown locally but has no distant spread (stage cT2-4a and/or lymph nodes N+, and M0), confirmed before surgery.
- Your cancer can be measured on scans (measurable tumor or lymph nodes on CT/MRI/PET-CT).
- Your general health is good enough for treatment and surgery (ECOG performance score 0–1).
- Your blood tests and organ function are within safe limits (including enough red cells, white cells, platelets, and normal liver/kidney tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of medicines given before surgery (neoadjuvant treatment) for stomach cancer that has grown locally but hasn’t spread to distant organs. It aims to shrink the tumor and improve outcomes by using several drugs together based on tumor features.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This Phase 3 trial tests an “immunotherapy first” approach before surgery for certain stomach (gastric) cancers. The goal is to increase immune cells inside the tumor, which may improve outcomes after surgery.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.